Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression

Inflammation Research

Volumn 60, Issue 7, 2011, Pages 643-653

  Gesser, B ^a   Rasmussen, M K ^a   Raaby, L ^a   Rosada, C ^a   Johansen, C ^a   Kjellerup, R B ^a   Kragballe, K ^a   Iversen, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

c Jun; Cox 2; CREB; DMF; MIF; MSK1; p53; RSK1

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; FUMARIC ACID DIMETHYL ESTER; LACTATE DEHYDROGENASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN AND STRESS ACTIVATED KINASE 1; PROTEIN C JUN; PROTEIN KINASE; PROTEIN P53; RIBOSOMAL S6 KINASE 1; S6 KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL NUCLEUS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KERATINOCYTE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DERMATOLOGIC AGENTS; FLAVONOIDS; FUMARATES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KERATINOCYTES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; PSORIASIS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051666137     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0316-7     Document Type: Article

References (48)

1. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005;11:43-8. (Pubitemid 40092674)
2. Stoof TJ, Flier J, Sampat S, et al. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol. 2001;144:114-20.
3. Loewe R, Pillinger M, De Martin R, et al. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-κB-dependent manner. J Invest Dermatol. 2001;117:1363-8. (Pubitemid 34032761)
4. Loewe R, Holnthoner W, Groøger M, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB in human endothelial cells. J Immunol. 2002;168:4781-7. (Pubitemid 34441387)
5. Gesser B, Johansen C, Rasmussen MK, et al. Dimethylfumarate specifically inhibits the mitogen and stress-activated kinase 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol. 2007;127:2129-37. (Pubitemid 47258496)
6. Otkjaer K, Kragballe K, Johansen C, et al. IL-20 gene expression is induced by IL-1β through mitogen-activated protein kinase and NF-κB dependent mechanism. J Invest Dermatol. 2007; 127:1326-36. (Pubitemid 46762975)
7. Shimizu T, Abe R, Nakamura et al. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999;264:751-758
8. Steinerhoff M, Meinhardt A, Steinhoff A, et al. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin diseases. Br J Dermatol. 1999;141:1061-6. (Pubitemid 30046196)
9. Shimizu T, Nishihira J, Mizue Y, et al. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol. 2001;116:989-90. (Pubitemid 32554390)
10. Wu J, Chen F, Zhang X, et al. Association of MIF promoter polymorphisms with psoriasis in a Han population in northeastern China. J Dermatol Sci. 2009;53:212-5.
11. Mitchell RA, Liao H, Chesney J et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 2002;99(1):345-50 (Pubitemid 34060365)
12. Hudson J, Shoaibi MA, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190:1375-82.
13. Lue H, Kaurniotu A, Fingerle-Rowson G, Roger T et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 2006; 18:688-703 (Pubitemid 43113299)
14. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68:320-44. (Pubitemid 38756868)
15. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev. 2002;12(1):14-21. (Pubitemid 34094984)
16. Deak M, Clifton AD, Lucocq JM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38 and may mediate activation of CREB. EMBO J. 1998;17:4426-41. (Pubitemid 28362632)
17. Wiggin GR, Soloaga A, Foster JM, et al. MSK1 and MSK2 are required for the mitogen-and stress-induced phophorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol. 2002;22:2871-81. (Pubitemid 34263007)
18. McCoy CE, Campbell DG, Deak M, et al. MSK1 activity is controlled by multiple phosphorylation sites. Biochem J. 2005;387:507-17. (Pubitemid 40571238)
19. Arthur JSM. MSK activation and physiological roles. Frontiers Biosci. 2008;13:5866-79.
20. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9:747-58.
21. Frödin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocr. 1999;151:65-77.
22. Carriere A, Ray H, Blenis J, Roux PP. The RSK factors of activating the Ras/MAPK signalling cascade. Front Biosci. 2008;13:4258-75. (Pubitemid 351611599)
23. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation- dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2:599-609 (Pubitemid 33674011)
24. McCoy CE, MacDonald A, Morrice NA et al. Identification of novel phosphorylation sites in MSK1 by precursor ion scanning MS. Biochem J. 2007;402:491-501 (Pubitemid 46423886)
25. Roux PP, Richards SA, J Blenisl. Phosphorylation of p90 Ribosomal S6 Kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol. 2003; 23:4796-4804 (Pubitemid 36793327)
26. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 1999;21:326-9. (Pubitemid 29124945)
27. Schreiber M, Kolbus A, Piu F, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999;13:607-19. (Pubitemid 29131884)
28. Whitmarsh-AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 1996;74(10):589-607
29. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20:2390-400. (Pubitemid 32531297)
30. Kleemann R, Hausser A, Geiger G, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000;408:211-6.
31. Kragballe K, Desjarlais L, Marcello CL. Increased DNA-synthesis of uninvolved psoriatic epidermis is maintained in vitro. Br J Dermatol. 1985;112:263-70. (Pubitemid 15127304)
32. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phophorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91(3):325-34. (Pubitemid 27467963)
33. Hendzel MJ, Wei Y, Mancini MA, Hooser AV, et al. Mitosisspecific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348-60. (Pubitemid 27510848)
34. Chou S, Baichwal V, JE Ferrell. Inhibition of c-Jun DNA binding by mitogen-activated protein kinase. Mol Biol Cell. 1992; 3:1117-30 (Pubitemid 23088962)
35. Thomson S, Mahadevan LC, Clayton AL. MAP kinases-mediated signalling to nucleosomes and immediate-early gene induction. Cell Dev Biol. 1999;10:205-14. (Pubitemid 129502412)
36. Funding AT, Johansen C, Kragballe K et al. Mitogen- and Stressactivated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol. 2006;126(1):784-91
37. Funding AT, Johansen C, Kragballe K, Iversen L. Mitogen- and stress-activated protein kinase 2 and cyclin AMP response element binding protein are activated in lesional psoriatic epidermis. J Invest Dermatol. 2007;127:2012-9. (Pubitemid 47075375)
38. Yalcin B, Tezel GG, Arda N, et al. Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase- 2 expression in psoriasis. Anal Quant Cytol Histol. 2007;29(6):358-64. (Pubitemid 350304993)
39. Shimizu T. Role of macrophage migration inhibitory factor in the skin. J Dermatol Sci. 2005;37:65-73. (Pubitemid 40126824)
40. Bech-Otschir D, Seeger M, Dubiel W. The COP9 signalosome: at the interface between transduction and ubiquitin-dependent proteolysis. J Cell Sci. 2002;115:467-73. (Pubitemid 34182974)
41. Minden A, Lin A, Smeal T, et al. c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinase. Mol Cell Biol. 1994;14:6683-8.
42. Cavigelli M, Dolfi F, Claret FX, Karin M. Induction of c-fos expression through JNK mediated TCF/ELK-1 phosphorylation. EMBO J. 1995;14(23):5957-64.
43. Milne DM, Campbell LE DG, Meek DW. P53 phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 1995;270(10):5511-8
44. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1 /JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA. 1998;95:10541-6. (Pubitemid 28413103)
45. Agarwal ML, Ramana CV, Hamilton M et al. Regulation of p53 expression by the RAS-MAPK kinase pathway. Oncogene. 2001;20:2527-36 (Pubitemid 32531349)
46. Johansen C, Flindt E, Kragballe K, et al. Inverse regulation of the nuclear factor-jB binding to the p53 and interleukin-8 response element in lesional psoriatic skin. J Invest Dermatol. 2005; 124:1284-92. (Pubitemid 40847417)
47. Johansen C, Kragballe K, Rasmussen M, et al. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. Br J Dermatol. 2004;151:600-7. (Pubitemid 39330884)
48. Haider AS, Duculan J, Whynot JA, Kruger JG. Increased JunB mRNA and protein expression in psoriasis vulgaris lesions. J Invest Dermatol. 2006;126:912-4.